HOME ABOUT CONTACT PREVIOUS ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Intelligent Sensor Informs You to Change a Diaper via SMS       » University of Manchester & A*STAR ongoing partnership- Joint PhD programme       » Philippines Healthcare & New Digital Platform, MyDoc.       » Tapping on ASEAN'S Healthcare Opportunities through Singapore       » ASEAN: The New Playing Field for Global Medical Device Companies       » The Burden of Great Potential: the ASEAN Economic Community & Biopharmaceuticals       » When there is no Queen in the house, Asian Hive Bees Avoid Risky Foraging for Reproduction       » XELJANZTM (Tofacitinib Citrate), A new class of treatment for Rheumatoid Arthritis Approved in Singapore      
EYE on CHINA
ScinoPharm Taiwan and Coland Holdings establish strategic alliance for oncological injectable products for China
ScinoPharm Taiwan Ltd. and Coland Holdings Ltd. have formed a strategic alliance to develop a series of generic oncological drugs for Mainland China. Several Active Pharmaceutical Ingredients (APIs) have been initially selected for development and future sales as injectable formulation products from the list of ScinoPharm-developed APIs. This will allow the companies to compete within the anti-cancer drug market in China and tap into this large and growing business potential.

This cooperation utilizes ScinoPharm’s process R&D and production advantages in the field of highly-potent oncological APIs and Coland’s well-established marketing capabilities in China to build an active presence within China’s rapidly growing anti-cancer drug market. Under the strategic alliance agreement, ScinoPharm will provide the APIs, a third party company will be commissioned to develop, formulate and register oncological  pharmaceutical products, and then Coland and ScinoPharm will be co-responsible for the marketing and sales efforts in the Chinese market. The currently selected and targeted anti-cancer products are mostly mainstream pharmaceuticals with large demand and high competitive barriers in the Chinese market, including treatments for lung, breast, and ovarian cancers, as well as MDS and pancreatic cancer. These products are estimated to reach the market in 2017 at the earliest. The market value within China for these products came to over 5 billion RMB (US$805 million) last year, demonstrating the immense future market potential resulting from this alliance.

Dr. Jo Shen, President and CEO of ScinoPharm, stated, “ScinoPharm is elated to form a strategic alliance with Coland. Resources from both parties will be combined to establish a robust collaboration for assertive development of products for the local anti-cancer medication market in China. This cooperation also marks ScinoPharm’s first move into Chinese market since launching our “Double A” strategy, combining unique APIs with Abbreviated New Drug Applications (ANDAs).  High technical entry barrier APIs will be continually developed into formulations (ANDAs), providing the Chinese pharmaceutical market with a total solution for domestic demand. This strategy will extend our marketing networks to cover end users resulting in securing and expanding ScinoPharm’s existing business while also enhancing the company’s long-term competitive advantage and new opportunities for growth.”

The CEO of Coland Holding Leo Lee stated: “Coland Holding is pleased to have the opportunity to work with world-leading API manufacturer, ScinoPharm, to develop oncology products for China Market. Following the rise of an aging population, along with environmental impact and changes in lifestyle, the overall market demand for anti-cancer drug has increased. Given that market entry for API production, formulation development and its subsequent sales process require higher level of technical standards, Coland is able to leverage its business expertise in managing medical platform in China, combined with ScinoPharm API technical capabilities, coupled with China’s CFDA intention to accelerate Anti-Cancer drug development that will speed up the registration process. This strategic alliance will be balancing complementary advantages from both partners, and expect to achieve large scale of synergies in developing China’s market.

The earlier study indicated the market size of China’s Oncology market was estimated 61.5 Billion RMB in 2011 – a 25% growth from preceding year. The reliance on cancer treatment drugs among all hospital medication had climbed to 2nd (2010) from 4th place (2002), next to the anti-infection drugs. Through the formation of strategic alliance, ScinoPharm and Coland aspire to act in response to the strong desirability of high quality oncology drugs in China, executing through strategic collaboration, and ensuring collective competitiveness are achieved in the niche anti-cancer  drug market.

Click here for the complete issue.

EDITORS' CHOICE  

Credits to: American Chemical Society
COLUMNS  

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy